Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma; HKEX: 02196, SSE: 600196) announced that its wholly-owned subsidiary, Chongqing Carelife Pharmaceutical Co., Ltd., has secured National Medical Products Administration (NMPA) approval for Sodium Thiosulfate Injection, targeting cyanide as well as arsenic, mercury, lead, bismuth and iodine poisoning cases. The approval expands the group’s emergency medicine portfolio and grants a drug approval number of “Guo Yao Zhun Zi H202636372.”

The newly approved product is a Category 3 chemical formulation with a specification of 4 ml: 1 g per vial. Chongqing Carelife is the marketing authorisation holder, while manufacturing will be undertaken by Yaopharma Co., Ltd.

Fosun Pharma has invested approximately RMB1.87 million in the compound’s research and development up to February 2026. According to IQVIA CHPA data, China’s market (excluding Hong Kong, Macau and Taiwan) for Sodium Thiosulfate formulations reached about RMB431.00 million in 2025, underscoring sizeable commercial potential within the antidote segment.

Management expects the approval to strengthen the group’s product pipeline; however, it cautions that actual sales will depend on medical demand, competitive dynamics and channel penetration, factors that could introduce variability to future revenue contributions.